Key result
A novel paclitaxel-eluting stent with programmable pharmacokinetics reduced late loss (0.3 vs 1.0 mm, P=0.04) compared with bare metal controls in a 30-day porcine coronary model.
Why the study?
Does a coronary stent with programmable pharmacokinetics loaded with paclitaxel reduce neointimal area and late loss compared to bare metal controls in a porcine coronary model?
Does a coronary stent with programmable pharmacokinetics loaded with paclitaxel reduce neointimal area and late loss compared to bare metal controls in a porcine coronary model?
Effect estimate: 70% reduction
Absolute Event Rate: 0.3% vs 1%
p-value: p=0.04
A novel layered polymer/drug inlay stent allows programmable paclitaxel release kinetics and significantly reduces neointimal hyperplasia in a porcine model.
No takes yet. Share an insight, caveat, or question.
Should not change clinical stent selection; leaves open translation of programmable paclitaxel release to human trials.
Finkelstein et al. (2003) studied Cardiovascular disease (n=17). Coronary stent with programmable pharmacokinetics (paclitaxel) vs. Bare metal controls was evaluated on Late loss (mm) (70% reduction, p=0.04). A novel paclitaxel-eluting stent with programmable pharmacokinetics reduced late loss (0.3 vs 1.0 mm, P=0.04) compared with bare metal controls in a 30-day porcine coronary model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: